Merck KGaA, a leading German healthcare and technology group, is reportedly in the final stages of negotiations to acquire Springworks Therapeutics, a U.S.-based biotech company. This development was disclosed by individuals familiar with the discussions, though no concrete agreement has yet been established.
About the Author
